| Literature DB >> 31723482 |
Antonio J Forte1, Maria T Huayllani1, Daniel Boczar1, Pedro Ciudad2, Oscar Manrique3.
Abstract
Lipoaspiration and venous lymph node transfer have each been described as procedures that would improve symptoms of lymphedema. We aim to describe the efficacy of the combination of lipoaspiration and lymph node transfer and to report the outcomes in breast cancer-related lymphedema patients. The search was conducted by querying the PubMed, EMBASE, and Ovid Medline databases for studies that considered the use of lipoaspiration and venous lymph node transfer as surgical treatment for breast cancer-related lymphedema. Different combinations of the keywords "aspiration lipectomy" AND "lymphedema" AND "lymph node transfer" were used for the search. From a total of 20 articles, five met inclusion criteria. All patients included in these studies had stage II or III lymphedema. Two studies considered lipoaspiration as the first step followed by lymph node transfer, two considered lymph node transfer as the first step followed by lipoaspiration, and one applied both procedures simultaneously. A meaningful volume reduction was achieved in all cases. Patients who underwent lymph node transfer first followed by lipoaspiration appeared to have the best outcomes. This systematic review suggests that the combination of lymph node transfer and lipoaspiration is a potential surgical treatment that may improve outcomes achieved by one single procedure in patients with stage II to III breast cancer-related lymphedema.Entities:
Keywords: breast cancer lymphedema; lipoaspiration; lymph node; lymph node transfer; lymphedema; microsurgery; microvascular free flap; plastic surgery; surgical treatment
Year: 2019 PMID: 31723482 PMCID: PMC6844538 DOI: 10.7759/cureus.6096
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Figure 1Inclusion and exclusion criteria
Studies to date assessing outcomes of lipoaspiration and lymph node transfer combined procedure
LN, lymph node transfer; LS, lipoaspiration
[1], [10-13]
| Author | Year | Type of Study | Sequence of Procedures | Time between procedures | Number of Patients | Age | Cause | Stage | Follow-up | Outcomes |
| Leppapuska IM et al. | 2019 | Prospective | Simultaneous | - | 48 (LN+LS = 21, LN = 27) | Mean: LN+LS = 56.7, LN = 50.2 | Breast cancer (n = 20), Hodgkin’s lymphoma (n = 1) | II | 52 months | Volume reduction greater in LN+LS group. |
| Agko M et al. | 2018 | Prospective | 1st: LN 2nd: LS | 6 to 8 months | 6 | Mean: 52 (range: 27-72) | Breast cancer | II | 23.5 months | Volume reduction, incidence of skin infections reduced |
| Cook KH et al. | 2016 | Case Report | 1st: LS 2nd: LN | 10 months | 1 | 52 | Breast cancer | III | 12 months | Volume reduction |
| Nicoli F et al. | 2015 | Prospective | 1st: LN 2nd: LS | 1 to 3 months | 10 | Mean: 54.6+/-9.3 | Breast cancer | - | - | Volume reduction |
| Granzow JW et al. | 2014 | Case Series | 1st: LS 2nd: LN | 11 months | 2 | 55 and 63 | Breast cancer | - | - | Volume reduction |